Report Overview

According to the deep-dive market assessment study by Growth Plus Reports, the global bioreactor market was valued at US$ 2.56 billion in 2021 and is expected to register a revenue CAGR of 16% to reach US$ 9.75 billion by 2030.

Market Fundamentals 

Bioreactors are manufacturing systems or containers used to grow organisms such as yeast, bacteria, or animal cells in a controlled environment. They maintain a favorable environment for cell growth and product formation. Bioreactors are used in the pharmaceutical and biological industries to produce vaccines, antibodies, and biological products. They are also used in industrial processes to grow organisms under controlled conditions and to manufacture pharmaceuticals for chronic disease treatment. These devices control and monitor the environmental conditions throughout the culture's ongoing reaction. The precise design and selection of bioreactors are critical for achieving a high output. This, in turn, aids in obtaining the necessary capital investment and increases the economic viability of the bioprocess.

[5454334]

Market Dynamics

The advancement of bioreactor features and processing will aid in the revenue growth of the bioreactor market. Manufacturers are constantly working to improve equipment to provide better control, ease of scaling up to process large volumes, and system simplification. Furthermore, advancements in design that allow for the cost-effective acceptance of single-use technologies would benefit business growth by providing benefits such as improved air and gas transfer efficiency, optimal cell mixing, and flexible operating conditions to maximize final outputs. Concerns about extractability affecting product quality and human health, on the other hand, would have a moderate impact on market revenue growth during the forecast period.

Market Ecosystem

The global bioreactor market is analyzed from four perspectives: material type, usage, end user, and region.

Bioreactor Market by Material Type

[87543]

Based on material type, the global bioreactor market is segmented into glass, stainless steel, and single-use. 

The single-use segment dominates the global bioreactor market and is expected to continue this trend during the forecast period. The rapid adoption of single use technologies (SUTs) by industries is expected to drive future market revenue growth. Single-use technology helps biopharmaceutical manufacturers to eliminate the risk of contamination, which is the most difficult challenge for biopharmaceutical manufacturers and increases operational efficiency by reducing or eliminating the need for sterilization between batches.

Bioreactor Market by Usage

Based on usage, the global bioreactor market is segmented into lab-scale production, pilot-scale production, and full-scale production. 

During the forecast period, the pilot-scale production segment will dominate the market due to an increase in the prevalence of chronic disease, advancements in the pharmaceutical and biotechnology industries, and growth in the number of pre-clinical trials and clinical studies. 

The full-scale production segment is expected to register significant revenue growth during the forecast period due to advancements in R&D activities for vaccine development and a surge in the adoption of advanced bioreactors.

Bioreactor Market by End User

Based on end user, the global bioreactor market is segmented into pharmaceutical and biopharmaceutical manufacturers, contract research organizations (CRO), academic & research institutes, and others. 

The pharmaceutical and biopharmaceutical manufacturers segment will dominate the global bioreactor market during the forecast period. A variety of pharmaceutical products are manufactured on an industrial scale through the bioprocessing of living cells. To drive high yield and productivity, traditional approaches are used to control various processes. Furthermore, monitoring and control of bioprocesses have become more complex as manufacturing processes have advanced, resulting in an increase in demand for advanced process control as well as the deployment of newer strategies for automation in the biopharmaceutical industry.

Bioreactor Market by Region

Based on the region, the global bioreactor market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). 

North America dominates the bioreactors market and is expected to continue to do so during the forecast period owing to the rise in the number of academic institutes in countries in the region and expanding R&D facilities. 

Asia Pacific is expected to register rapid revenue growth during the forecast period. The rapid increase in population and the rising prevalence of chronic diseases are major factors driving pharmaceutical manufacturing. The rapid growth in the pharmaceutical industry in the region due to the availability of low-cost Active Pharmaceutical Ingredients (API) and labor are increasing the demand for bioreactors and fermenters for drug development.

Competitive Landscape

The key players operating the global bioreactor market are:

• BBI-Biotech GmbH
• Danaher Corporation
• Bioengineering AG
• Eppendorf AG
• Getinge
• Sartorius AG
• Infors HT
• Merck KgaA
• Thermo Fisher Scientific, Inc
• Solaris Biotech Solutions

To gain a strong position in the market, these key players are pursuing various strategies such as R&D investments, license agreements, partnerships, mergers and acquisitions, collaborations, and joint ventures.

Strategic Developments

• In February 2021, The MFG5 Drug Substance (DS) manufacturing facility of WuXi Biologics in China successfully launched a GMP operation with a capacity of 36,000L and nine 4,000L single-use bioreactors. The GMP launch of MFG5 marks a significant milestone in the company's global capacity planning, bringing WuXi Biologics' current capacity to 90,000L, significantly increasing the company's ability to enable global partners.
• In February 2020, Eppendorf introduced the SciVario twin, a bioreactor controller system for small bench-scale bioreactors. The goal of this launch was to enable remote monitoring of cell culture processes and to expand the company's product portfolio.
• In January 2020, Getinge has acquired Applikon Biotechnology B.V., a leader in the supply and development of advanced bioreactor systems (Sweden). The acquisition was intended to strengthen Getinge's Life Science business segment.
• In April 2019, Freeline (UK), a leading biotechnology company, partnered with Pall Corporation (US). The goal of this collaboration is to integrate the iCELLis bioreactor system into Freeline's adeno-associated virus (AAV) manufacturing platform. Furthermore, this collaboration will improve the quality of adeno-associated virus gene therapy vector production.

Frequently Asked Questions About This Report